Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Sarepta Eyes Patient Outcomes To Boost Exondys 51's European Review

Jan 28 2017

• By Derrick Gingery

close up of an eye

Related Content

Sarepta Must Balance Exondys 51 Confirmatory Trials And Sales

Sep 23 2016

J.P. Morgan Notebook Day 2: Bristol Humbled By Competition, Sanofi’s Sarilumab Ready For Review, Justifying Spinraza’s Price And More

Jan 11 2017

‘File Over Protest’ At US FDA: PTC To Pursue Rarely-Used Pathway For DMD Drug

Jan 10 2017

Duchenne Group's Presentation Is Milestone For Patient Involvement

May 02 2016

Sarepta's Shadow: BioMarin Mulls Turning The Extraordinary Into A Template

Oct 15 2016

Patients Can't Rescue Sarepta's Eteplirsen

Apr 26 2016

Sarepta's Additional Data Doesn't Sway FDA On Eteplirsen

Apr 21 2016

Duchenne Muscular Dystrophy: Second Product Isn't The Charm

Jan 15 2016

Sarepta's Eteplirsen Approved After Contentious Internal FDA Debate

Sep 20 2016

No More Sarepta-Like Development, FDA Officials Say

Oct 20 2016

Related Companies

Sarepta Therapeutics, Inc.

BioMarin Pharmaceutical Inc.

PTC Therapeutics, Inc.

Additional Topics

United States Europe Rare Diseases Market Access Regulation Drug Review Business Strategies BioPharmaceutical

More from Rare Diseases

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window